Trophic Factor Signaling and Motor Neuron Death
营养因子信号传导和运动神经元死亡
基本信息
- 批准号:7569972
- 负责人:
- 金额:$ 28.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-02-15 至 2011-01-31
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseAdenosine A2A ReceptorAmyotrophic Lateral SclerosisAnimal ModelAnimalsBasic ScienceBiochemicalBrainBrain-Derived Neurotrophic FactorCategoriesCell Culture TechniquesCessation of lifeControl GroupsDegenerative DisorderDevelopmentDoseDrug Delivery SystemsEmbryoEventFamilyFunctional disorderFutureGene ExpressionGenesGlutamate ReceptorGlutamatesGrowth FactorHumanIn VitroIndividualInositolInvestigationK 252aLipidsMotor Neuron DiseaseMotor NeuronsMutationNerve Growth FactorsNeuronsNeurotrophic Tyrosine Kinase Receptor Type 2PDPK1 genePathologicPatientsPeptidesPharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePhosphatidylinositolsPhosphorylationPhosphotransferasesPlayProcessProtein Tyrosine KinasePublishingPurinergic P1 ReceptorsRandomizedRecombinantsRodentRoleSerineSignal PathwaySignal TransductionSpecificitySpinal CordTissuesToxic effectTranslatingTyrosine Kinase InhibitorWorkbaseeffective therapyenprofyllineexcitotoxicityin vivoinhibitor/antagonistinorganic phosphatekillingsmotor neuron degenerationmotor neuron developmentmutantneurotransmissionnovelpreventreceptortissue culture
项目摘要
The central pathologic event in Amyotrophic Lateral Sclerosis (ALS) is the selective degeneration of motor
neurons. While most cases (-90%) are sporadic, the familial cases are due to mutations in a variety of
different genes such as SOD1 and p150glued. Excessive activation of glutamate receptors (excitotoxicity)
is an early triggering event. The death of motor neurons from excitoxic insult or mutant gene expression
can be studied in cell culture using dissociated rodent embryonic spinal cord tissue. Our previous in vitro
work demonstrates that excitotoxic motor neuron death only occurs if Brain-derived neuronotrophic factor
(BDNF) signaling via TrkB is intact. The phosphatidylinositol 3' kinase (PIS'K) signaling cascade is activated
by TrkB and PIS'K signaling is necessary and sufficient for BDNF-induced excitotoxic death of motor
neuron. Pharmacological manipulations that inhibit Trk activation can also protect motor neurons from the
toxic effects of mutant SOD1 and p150glued. This can be accomplished using proprietary derivatives of
K252a (made by Cephalon Pharmaceuticals) or by inhibiting the activation of adenosine A2A receptors. In
specific aim #1 we will examine the alterations in intracellular signaling cascades that follow from
administration of these agents. The potential interplay between mutant SOD1 and p150glued and Trk
signaling events will also be studied. In specific aim #2, we will study the in vivo pharmacodynamics of
these agents on Trk activation and signaling. This is a prelude to future studies in which we hope to
examine the efficacy of these agents in animal models of ALS. In specific aim #3 we will study the signaling
cascades downstream of activated PIS'K (two serine-theonine kinases (PDK1, Akt) and small monomeric
GTP'ases of the RhoA and Arf families) to see which is needed to evoke excitotoxic sensitivity of motor
neurons. This will define susceptiblity-to-toxicity intracellular signaling pathways in motor neurons.
Relevance: The proposed work attempts to translate basic science observations into new treatments for
ALS. The development of new drug targets for ALS could guide the way for novel therapies for other, more
prevalent, neuro-degenerative disorders.
肌萎缩侧索硬化症(ALS)的中心病理事件是选择性运动变性
神经元。虽然大多数病例(-90%)是零星的,但家族性病例是由于各种基因突变所致。
不同的基因如SOD1和p150粘合在一起。谷氨酸受体过度激活(兴奋性毒性)
是一个早期的触发事件。兴奋性损伤或突变基因表达导致运动神经元死亡
可以在使用分离的啮齿动物胚胎脊髓组织的细胞培养中进行研究。我们之前的试管婴儿
研究表明,兴奋性运动神经元死亡只有在脑源性神经营养因子
(BDNF)通过TrkB的信号是完整的。磷脂酰肌醇3‘激酶(PiS’K)信号通路被激活
TrkB和PiS‘K信号通路是BDNF诱导的兴奋性中毒性马达死亡的充要条件
神经元。抑制Trk激活的药物操作也可以保护运动神经元免受
突变体sod1和p150的毒性效应。这可以使用专有的
K252a(由Cephalon制药公司制造)或通过抑制腺苷A2a受体的激活。在……里面
具体目标#1我们将检查以下细胞内信号级联的变化
这些代理的管理。突变体SOD1与p150gled和Trk之间的潜在相互作用
信令事件也将被研究。在特定的目标#2,我们将研究在体内的药效学
这些药物对Trk的激活和信号转导有影响。这是我们希望进行的未来研究的前奏
在肌萎缩侧索硬化症动物模型中检查这些药物的疗效。在具体目标#3中,我们将研究信令
激活的PiS‘K(两个丝氨酸茶氨酸激酶(PDK1,Akt)和小单体)下游级联
RhoA和Arf家族的GTP),以了解哪一种需要唤起电机的兴奋性毒性敏感性
神经元。这将定义运动神经元对毒性的易感性细胞内信号通路。
相关性:拟议的工作试图将基础科学观察转化为新的治疗方法
肌萎缩侧索硬化。针对肌萎缩侧索硬化症的新药靶点的开发可以为其他、更多的
普遍存在的神经退行性疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert G Kalb其他文献
Robert G Kalb的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert G Kalb', 18)}}的其他基金
Defining mechanisms underlying C9orf72-associated frontotemporal dementia with C. elegans and mammalian models
用线虫和哺乳动物模型定义 C9orf72 相关额颞叶痴呆的机制
- 批准号:
10552038 - 财政年份:2022
- 资助金额:
$ 28.75万 - 项目类别:
Defining mechanisms underlying C9orf72-associated frontotemporal dementia with C. elegans and mammalian models
用线虫和哺乳动物模型定义 C9orf72 相关额颞叶痴呆的机制
- 批准号:
10342721 - 财政年份:2022
- 资助金额:
$ 28.75万 - 项目类别:
Cytohesins, ARF GTP'ases and Neurodegeneration
细胞粘附素、ARF GTP 酶和神经变性
- 批准号:
9605921 - 财政年份:2017
- 资助金额:
$ 28.75万 - 项目类别:
Cytohesins, ARF GTP'ases and Neurodegeneration
细胞粘附素、ARF GTP 酶和神经变性
- 批准号:
9275554 - 财政年份:2016
- 资助金额:
$ 28.75万 - 项目类别:
相似海外基金
Mechanism of allosteric action of extracellular ATP at the adenosine A2a receptor
细胞外 ATP 对腺苷 A2a 受体的变构作用机制
- 批准号:
570072-2022 - 财政年份:2022
- 资助金额:
$ 28.75万 - 项目类别:
Postgraduate Scholarships - Doctoral
Targeting the Host Adenosine A2A Receptor to Protect Against Fatal Rickettsiosis Using an Approved Parkinson's Disease Drug
使用经批准的帕金森病药物靶向宿主腺苷 A2A 受体来预防致命的立克次体病
- 批准号:
9510124 - 财政年份:2018
- 资助金额:
$ 28.75万 - 项目类别:
Structure and Dynamics of Adenosine A2A receptor - Gs Complexes
腺苷 A2A 受体 - Gs 复合物的结构和动力学
- 批准号:
382662 - 财政年份:2018
- 资助金额:
$ 28.75万 - 项目类别:
Operating Grants
Understanding the Allosteric Regulation of Adenosine A2A Receptor by Metal Cations
了解金属阳离子对腺苷 A2A 受体的变构调节
- 批准号:
515106-2017 - 财政年份:2017
- 资助金额:
$ 28.75万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients
靶向肺癌患者的腺苷 A2A 受体免疫检查点
- 批准号:
9175600 - 财政年份:2016
- 资助金额:
$ 28.75万 - 项目类别:
Molecular imaging of adenosine A2A receptor: a first-in-human study
腺苷 A2A 受体的分子成像:首次人体研究
- 批准号:
16H05396 - 财政年份:2016
- 资助金额:
$ 28.75万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Anti-inflammatory activities of the adenosine A2A receptor in human neutrophils: delineation of resolution and anti-ageing pathways
人中性粒细胞中腺苷 A2A 受体的抗炎活性:解析和抗衰老途径的描述
- 批准号:
351807 - 财政年份:2016
- 资助金额:
$ 28.75万 - 项目类别:
Operating Grants
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients
靶向肺癌患者的腺苷 A2A 受体免疫检查点
- 批准号:
9462266 - 财政年份:2016
- 资助金额:
$ 28.75万 - 项目类别:
Effects of Adenosine A2a receptor deficiency on a-synuclein-induced neurotoxicity
腺苷 A2a 受体缺陷对 a-突触核蛋白诱导的神经毒性的影响
- 批准号:
15K09308 - 财政年份:2015
- 资助金额:
$ 28.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Adenosine A2A receptor cross-activation of TrkB in Huntington's disease
亨廷顿病中 TrkB 的腺苷 A2A 受体交叉激活
- 批准号:
8104912 - 财政年份:2011
- 资助金额:
$ 28.75万 - 项目类别:














{{item.name}}会员




